Stay updated on XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial

Sign up to get notified when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.2 to version 2.16.3.
    Difference
    0.1%
    Check dated 2025-06-13T15:48:18.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-06T11:38:35.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-30T06:35:56.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.3%
    Check dated 2025-05-23T04:47:31.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-01T14:22:41.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    The web page has undergone significant updates regarding a clinical study on XMT-1592, specifically changing the focus from a Phase 1b trial to an open-label, dose escalation study targeting patients with platinum-resistant ovarian cancer and non-squamous NSCLC. Key details about the study's design, including the maximum tolerated dose (MTD) confirmation process and the inclusion of collaborators, have been clarified.
    Difference
    34%
    Check dated 2025-04-17T02:22:04.000Z thumbnail image

Stay in the know with updates to XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the XMT-1592 Study in NaPi2b+ Ovarian Cancer & NSCLC Clinical Trial page.